Prax­is' epilep­sy drug re­duces seizures by 46% in pe­di­atric pa­tients in Phase 2 study

Prax­is Pre­ci­sion Med­i­cines re­leased an­oth­er batch of topline da­ta from its epilep­sy pro­gram on Tues­day, this time from the Phase 2 EM­BOLD study in­ves­ti­gat­ing re­lut­rig­ine …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER